Welcome, Guest. Please login or register.
December 26, 2024, 03:49:19 am

Login with username, password and session length


Members
  • Total Members: 6315
  • Latest: DRG
Stats
  • Total Posts: 55137
  • Total Topics: 4855
  • Online Today: 650
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 150
Total: 150

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Novel Thyroid Hormone Receptor Agonists Show Promise for MASH  (Read 1234 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 191
Novel Thyroid Hormone Receptor Agonists Show Promise for MASH
« on: December 09, 2024, 10:30:18 am »
Two experimental thyroid hormone receptor agonists, VK2089 and ALG-055009, led to significant improvements in people with metabolic dysfunction-associated steatohepatitis (MASH), according to late-breaking study results presented at the American Association for the Study of Liver Diseases Liver Meeting 2024.

One study showed that up to 75% of people treated with VK2809, from Viking Therapeutics, achieved MASH resolution with no worsening of liver fibrosis at 52 weeks. In another study, Aligos Therapeutics’ ALG-055009 led to a reduction in liver fat at 12 weeks, supporting further evaluation.

Read more...
https://www.hepmag.com/article/novel-thyroid-hormone-receptor-agonists-show-promise-mash

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.